Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.

doi:10.1111/tid.12696

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.

Transplant infectious disease : an official journal of the Transplantation Society - 1 Jun 2017

Forns Xavier, Berenguer Marina, Herzer Kerstin, Sterneck Martina, Donato Maria Francesca, Andreone Pietro, Fagiuoli Stefano, Cieciura Tomasz, Durlik Magdalena, Calleja Jose Luis, Mariño Zoe, Shukla Umesh, Verbinnen Thierry, Lenz Oliver, Ouwerkerk-Mahadevan Sivi, Peeters Monika, Janssen Katrien, Kalmeijer Ronald, Jessner Wolfgang

Abstract excerpt

BACKGROUND: Recurrent hepatitis C virus (HCV) infection following liver transplantation is associated with accelerated progression to graft failure and reduced patient survival. METHODS: The Phase II, open-label SATURN study (NCT01938625) investigated the combination of simeprevir (SMV), daclatasvir (DCV), and ribavirin (RBV) administered for 24 weeks in 35 patients with recurrent HCV genotype (GT) 1b infection...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclosporine

Share to Graft Rejection

Share to Imidazoles

Share to Liver Transplantation

Share to Pyrrolidines

Share to Simeprevir

Share to Tacrolimus

Source

Open in PubMed

Identifiers

PMID: 28295849
DOI: 10.1111/tid.12696

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.PMID 28295849Read ↗

Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.Semantic proximity Read ↗

Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Semantic proximity Read ↗

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.Semantic proximity Read ↗

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.Semantic proximity Read ↗

Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.Semantic proximity Read ↗

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.Semantic proximity Read ↗

Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.Semantic proximity Read ↗

Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.Semantic proximity Read ↗

Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.Semantic proximity Read ↗

Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.Semantic proximity Read ↗

Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.Semantic proximity Read ↗

Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.